HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

Overexpression of HER2 is an important prognostic marker, and the only predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. HER2-HER3 dimer has been shown to drive proliferation and tumor progression, and targeting of this dimer with pertuzumab alongside chemotherap...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Weitsman, Gregory, Barber, Paul R., Nguyen, Lan K., Lawler, Katherine, Patel, Gargi, Woodman, Natalie, Kelleher, Muireann T., Pinder, Sarah E., Rowley, Mark, Ellis, Paul A., Purushotham, Anand D., Coolen, Anthonius C., Kholodenko, Boris N., Vojnovic, Borivoj, Gillett, Cheryl, Ng, Tony
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5239455/
https://ncbi.nlm.nih.gov/pubmed/27618787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9963
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires